How CNBC Cures is bringing rare disease stories to a national audience
Last summer, my sister Becky approached me with an idea. She wanted my help building a platform at…
Readout Newsletter: Eli Lilly’s ‘triple-G’ drug delivers striking results
Regulators are trying to push drug development into a post-animal testing era. Meanwhile, a Jennifer Doudna-founded company is…
FDA approves high dose version of Novo Nordisk’s obesity drug Wegovy
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark,…
Eli Lilly’s obesity drug retatrutide clears late-stage diabetes trial
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike…
With Trump in office, an ALS cure seems farther than ever
For almost a decade, I’ve fought for a cure for a disease I don’t even have yet. In…
Nonprofit launches with $500M to modernize scientific process for AI era
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and…
Vertex says drug reduced marker of kidney disease in late-stage trial
Vertex said Monday that a drug it secured as part of a $4.9 billion acquisition successfully reduced by…
FDA, urged to avoid controversy, creates new headache with attack on UniQure
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
TrumpRx: High expectations, but limited impact a month after launch
WASHINGTON — President Trump heralded his signature drug discount platform, TrumpRx, as “one of the most transformative health…
Eli Lilly launches program to boost employer coverage of obesity drugs
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the…
Why ‘quantum proteins’ could be the next big thing in biology
Crystal jellyfish have an eerie beauty: thanks to a natural protein, they emit a faint green glow. For…
Gilead to buy Arcellx in nearly $8B deal
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…